drugset / Trial / NCT01383499

A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma

NCT01383499

Phase 2 Completed 101 enrolled Boehringer Ingelheim Pfizer · collab
RandomizedCrossoverQuadruple-blindTreatment

Summary

The aim of this trial is to select an optimum dose may be selected based on bronchodilator efficacy, safety evaluations and pharmacokinetics of tiotropium bromide.

Timeline

Start
2011-08
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Tiotropium Other / unclassified 1.25 ug Inhaled
Subject Tiotropium Other / unclassified 2.5 ug Inhaled
Subject Tiotropium Other / unclassified 5 ug Inhaled

Indications